Cellyan Biotechnology Co., Ltd (HKPD) Form 6-K — Sep 23, 2026
Cellyan Biotechnology shareholders approved a 1-for-20 share consolidation of its Class A and Class B ordinary shares at an extraordinary general meeting on September 21, 2026, with over 360.9 million votes in favor and only about 6,800 against. Every 20 shares of US$0.001 par value will be consolidated into one share of US$0.02 par value, cutting authorized shares from 1 billion to 50 million, effective on a date confirmed by Nasdaq. Shareholders also approved a fifth amended and restated memorandum and articles of association to reflect the consolidation.
Key figures
- Reverse split ratio
- 1:20
- Record date
- 2026-09-09
- Quorum votes
- 360895958
- Quorum percent
- 90.29%
- Par value change
- US$0.001 to US$0.02 per share
- New authorized capital
- US$1,000,000 divided into 50,000,000 shares (47,000,000 Class A, 3,000,000 Class B)
- Total votes outstanding
- 399667457
- Votes for consolidation
- 360889111
- Votes against consolidation
- 6847
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.